SEP 09, 2016 05:33 AM PDT

Cord Blood Transplants Are Often A Better Option

Many cancer patients with leukemia will undergo stem cell transplants as part of their treatment plan. The problem is that donor cells must be a genetic match to the recipient and it’s sometimes difficult to find a person who matches and can donate. An alternative treatment is an umbilical cord blood transplant. Research on this procedure was published recently in the New England Journal of Medicine and offers new hope for some patients. 
Cord blood cells don't have to be a perfect genetic match
A study, led by researchers at the Fred Hutchinson Cancer Research Center in collaboration with Seattle Cancer Care Alliance, found that cord blood transplants have better outcomes in patients that would normally have a high risk of relapse than transplants using stem cells from unrelated donors. The research looked at leukemia patients as well as those who had a related bone marrow disorder, myelodysplastic syndrome.
 
When a transplant is needed, there are three possible sources. Bone marrow, peripheral blood stem cells (PBSCs) and cord blood. The ideal situation is that a patient has a familial match from either the bone marrow or PBSCs of a relative. Matches are genetically based. The human leukocyte antigen, or HLA, type genes coded into each person’s unique genetic background are the lynch pin to a successful transplant. It is the similarity between the donor HLA genes and the recipients genes that determines the odds of the donor stem cells being rejected or accepted. Typically a 10-out of-10 match of HLA genes between patients and their donors is the gold standard, but it doesn’t happen that often. Without that kind of match, a transplant can be done with an 8 out of 10 match or a 9 out of 10 and while these are better than nothing, for patients at a high risk for relapse the odds of success are low.
 
The benefit of using cord blood is that unlike adult stem cells, cord blood cells are not fully developed and a high genetic match is not as crucial as it is when using adult donor cells. Cord blood cells can match many more recipients. Since some genes are tied to ethnic backgrounds it’s not unheard of for two unrelated people, donor and recipient, being a match based on ethnicity rather than HLA genes.
 
In addition to the high stakes of a genetic match, there are those patients who are at an even higher risk of relapse. Chemotherapy, while required in these cases before a transplant can be done, does not always wipe out all of the disease. The prognosis for this group of high risk patients who have what is called “minimal residual disease” is usually pretty poor, with less than 1/3 of them remaining alive three years after treatment. The recent study suggests cord blood transplants could be a better decision for this risk category.
 
In the study Drs. Fillilpo Milano and Colleen Delaney looked at the outcomes of 582 patients who received stem cell transplants from 2006, when the institute’s Cord Blood Program launched, to 2014. Of those, 140 patients received cord blood transplants. The results revealed that the probability of overall survival after receipt of a transplant from a cord-blood donor was at least as high as those patients who got a transplant from an HLA-matched unrelated donor. When comparing patients who received cells from an HLA-mismatched unrelated donor, the cord blood recipients had a higher survival rate. Relapse rates were lower in the cord blood group as well.
 
In a press release about the study, Dr. Delaney stated, “This brings home the point that cord blood shouldn’t be called an alternative donor. The outcomes are the same as a conventional donor. This paper shows that if you’ve got high-risk disease and are at high risk for relapse post-transplant, transplant with a cord blood donor may be the best option.” Learn more about this new information in the video below.

Sources: Fred Hutchinson Cancer CenterNew England Journal of Medicine  
National Marrow Donor Program
About the Author
  • I'm a writer living in the Boston area. My interests include cancer research, cardiology and neuroscience. I want to be part of using the Internet and social media to educate professionals and patients in a collaborative environment.
You May Also Like
DEC 15, 2019
Genetics & Genomics
DEC 15, 2019
Rare Gene Mutation Prevents Memory Problems Brought on by Sleep Deprivation
A few rare people can get by with less sleep than the rest of us; after only four to six hours they are well-rested....
DEC 15, 2019
Genetics & Genomics
DEC 15, 2019
Can CRISPR Replace Antibiotics?
Antibiotic-resistant infections claim around 700,000 lives per year, with estimates saying that this number could swell to 10 million by 2050 (Jacobs: 2019...
DEC 15, 2019
Genetics & Genomics
DEC 15, 2019
New Way to Determine What Our Genes Do
Geneticists at the University of Virginia (UVA) School of Medicine have developed a new way to determine what our genes do. This will not only allow scient...
DEC 15, 2019
Genetics & Genomics
DEC 15, 2019
Mining 'Junk' DNA for New Cancer Therapeutics
There are vast portions of the genome that don't code for protein, but researchers are learning more about how important they are....
DEC 15, 2019
Genetics & Genomics
DEC 15, 2019
Promising New Treatment for Mitochondrial Disease Found in Fruit Flies
Researchers at the University of Cambridge have discovered a protein in fruit flies that can reverse the effects of harmful mutations in mitochondrial gene...
DEC 15, 2019
Genetics & Genomics
DEC 15, 2019
Finding a Way to Treat Dangerous Protein Aggregates
The scientists are hopeful that this work will lead to new therapeutics for neurodegenerative disease....
Loading Comments...